I agree that this site is using cookies. You can find further informations here.
X
Backes, Floor J.
223  results:
?
1

Associations between race and ethnicity and treatment setti..:

Meade, Caitlin E. ; Sinnott, Jennifer A. ; Backes, Floor J....
Gynecologic Oncology.  188 (2024)  - p. 111-119 , 2024
Link: https://doi.org/10.1016/..
 
?
2

Phase II trial of pembrolizumab and epacadostat in recurren..:

Gien, Lilian T. ; Enserro, Danielle M. ; Block, Matthew S....
Gynecologic Oncology.  186 (2024)  - p. 61-68 , 2024
Link: https://doi.org/10.1016/..
 
?
3

RETRACTED: Cost-effectiveness of chemotherapy and dostarlim..:

Riedinger, Courtney J. ; Barrington, David A. ; Nagel, Christa I....
Gynecologic Oncology.  183 (2024)  - p. 78-84 , 2024
Link: https://doi.org/10.1016/..
 
?
4

Progression-free survival and safety at 3.5 years of follow..:

González-Martín, Antonio ; Pothuri, Bhavana ; Vergote, Ignace...
Future Oncology.  , 2024
Link: https://doi.org/10.2217/..
 
?
5

Retraction notice to "Cost-effectiveness of chemotherapy an..:

Riedinger, Courtney J. ; Barrington, David A. ; Nagel, Christa I....
Gynecologic Oncology.  183 (2024)  - p. R1 , 2024
Link: https://doi.org/10.1016/..
 
?
6

Does the choice of platinum doublet matter? A study to eval..:

Levine, Monica D. ; Wang, Heather ; Sriram, Bhargavi...
Gynecologic Oncology.  182 (2024)  - p. 51-56 , 2024
Link: https://doi.org/10.1016/..
 
?
7

Lunchbox trial: A randomized phase III trial of cisplatin a..:

Barlin, Joyce N. ; Mahar, Barb ; Ata, Ashar...
Gynecologic Oncology.  180 (2024)  - p. 63-69 , 2024
Link: https://doi.org/10.1016/..
 
?
8

Recurrence rate in early-stage epithelial ovarian cancer: I..:

Levine, Monica D. ; O'Malley, David M. ; Haight, Paulina J....
Gynecologic Oncology Reports.  46 (2023)  - p. 101173 , 2023
Link: https://doi.org/10.1016/..
 
?
9

Carboplatin dosing in the treatment of ovarian cancer: An N..:

Praiss, Aaron M. ; Miller, Austin ; Smith, Judith...
Gynecologic Oncology.  174 (2023)  - p. 213-223 , 2023
Link: https://doi.org/10.1016/..
 
?
10

Epigenetic MMR defect identifies a risk group not accounted..:

Riedinger, Courtney J. ; Brown, Morgan ; Haight, Paulina J....
Frontiers in Oncology.  13 (2023)  - p. , 2023
Link: https://doi.org/10.3389/..
 
?
11

Progression-free survival and safety at 3.5 years of follow..:

González-Martín, Antonio ; Pothuri, Bhavana ; Vergote, Ignace...
European Journal of Cancer.  189 (2023)  - p. 112908 , 2023
Link: https://doi.org/10.1016/..
 
?
12

Do Not Forget about Hormonal Therapy for Recurrent Endometr..:

Wagner, Vincent M. ; Backes, Floor J.
Cancers.  15 (2023)  6 - p. 1799 , 2023
Link: https://doi.org/10.3390/..
 
?
13

Pembrolizumab versus placebo in addition to carboplatin and..:

Eskander, Ramez ; Sill, Michael ; Beffa, Lindsey...
Gynecologic Oncology.  176 (2023)  - p. S42-S43 , 2023
Link: https://doi.org/10.1016/..
 
?
14

NRG‐GY012: Randomized phase 2 study comparing olaparib, ced..:

Rimel, Bobbie J. ; Enserro, Danielle ; Bender, David P....
Cancer.  130 (2023)  8 - p. 1234-1245 , 2023
Link: https://doi.org/10.1002/..
 
?
15

"More than a song and dance": Exploration of patient perspe..:

Morton, Molly ; Haight, Paulina J. ; Khadraoui, Wafa...
Gynecologic Oncology.  175 (2023)  - p. 81-87 , 2023
Link: https://doi.org/10.1016/..
 
1-15